Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma

Ghassan K. Abou-Alfa, S. Qin, B. Y. Ryoo, S. N. Lu, C. J. Yen, Y. H. Feng, H. Y. Lim, F. Izzo, M. Colombo, D. Sarker, L. Bolondi, G. Vaccaro, W. P. Harris, Z. Chen, R. A. Hubner, T. Meyer, W. Sun, J. J. Harding, E. M. Hollywood, J. MaP. J. Wan, M. Ly, J. Bomalaski, A. Johnston, C. C. Lin, Y. Chao, L. T. Chen

Research output: Contribution to journalArticlepeer-review

52 Scopus citations

Fingerprint Dive into the research topics of 'Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences